Nick Leschly (Bluebird Bio Inc. (Nasdaq: BLUE))

Leschly, Nick (Bluebird Bio 201606 CEO)

	Organisation	Bluebird Bio Inc. (Nasdaq: BLUE)
	Group	Bluebird Bio (Group)
	Former/major organisation	Proclara Biosciences Inc.
	Product	Lenti-D™ gene therapy product
	Product 2	Zynteglo™ (autologous CD34+ cells encoding ß A-T87Q-globin gene, formerly LentiGlobin™)

Record changed: 2023-12-16

Picture Berlin Partner Top News CareSyntax Raises $180m Funding 650x200px

More documents for Nick Leschly

[1] Apceth Biopharma GmbH. (5/11/20). "Press Release: Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with bluebird bio". Allendale, NJ & Munich....
[2] Bluebird Bio, Inc.. (6/3/19). "Press Release: Bluebird Bio Announces EU Conditional Marketing Authorization for Zynteglo (autologous CD34+ cells encoding ßA-T87Q-globin gene) Gene Therapy". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]